Flupenthixol Treatment in Schizophrenic Cocaine Abusers - 1

This study has been completed.

First Received: September 20, 1999 Last Updated: June 23, 2005 History of Changes

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) New York State Psychiatric Institute
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000266

Purpose

The purpose of this study is to evaluate the safety and efficacy of flupenthixol for cocaine dependence in individuals with schizophrenia/schizoaffective illness.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Flupenthixol	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Flupenthixol Treatment in Schizophrenic Cocaine Abusers

Resource links provided by NLM:

Drug Information available for: Cocaine hydrochloride Flupenthixol decanoate Flupenthixol

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Side effects
Craving
Drug use
Psychiatric symptoms

Estimated Enrollment:	0
Study Start Date:	August 1994
Estimated Study Completion Date:	December 2001

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000266

Locations

United States, New York
New York State Psychiatric Institute
New York, New York, United States, 10032

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

New York State Psychiatric Institute

Investigators

Principal Investigator:

Herbert Kleber, M.D.

New York State Psychiatric Institute

More Information

No publications provided

Study ID Numbers:	NIDA-09236-1, P50-09236-1
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000266 History of Changes
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Cocaine-Related Disorders
Flupenthixol
Neurotransmitter Agents
Tranquilizing Agents
Flupenthixol decanoate
Psychotropic Drugs
Disorders of Environmental Origin

Central Nervous System Depressants
Antipsychotic Agents
Dopamine
Mental Disorders
Substance-Related Disorders
Dopamine Agents
Cocaine

Additional relevant MeSH terms:

Cocaine-Related Disorders
Flupenthixol
Neurotransmitter Agents
Tranquilizing Agents
Molecular Mechanisms of Pharmacological Action
Flupenthixol decanoate
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Depressants

Disorders of Environmental Origin
Dopamine Antagonists
Antipsychotic Agents
Pharmacologic Actions
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Dopamine Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on July 02, 2009